{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-021061","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.405370+00:00","generated_at":"2026-06-24T04:42:14.446422+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arrowhead Q3 FY2022 revenue $32.4M, net loss $72.0M; pipeline progresses","bullets":["Q3 FY2022 revenue $32.4M (down 29% YoY); net loss $72.0M ($0.68 loss per share) vs $29.9M loss prior year.","Total cash & investments $582.4M, down from $613.4M at Sept 2021; operating loss $72.9M.","Phase 2 fazirsiran: fibrosis regression in 58%, median 83% reduction in Z-AAT accumulation in liver.","Initiated Phase 1/2a for ARO-MUC5AC and ARO-RAGE; Phase 2 GATEWAY for ARO-ANG3 in HoFH started.","Hired Tracie Oliver as CCO; promoted Patrick O'Brien to COO; formed JV Visirna Therapeutics with Vivo Capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-021061","json":"https://secwatch.observer/filing/0001628280-22-021061.json","markdown":"https://secwatch.observer/filing/0001628280-22-021061.md","text":"https://secwatch.observer/filing/0001628280-22-021061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000162828022021061/0001628280-22-021061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000162828022021061/arwr-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:42:14.446422+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}